Amid Moderna's 'transition year,' CEO Stéphane Bancel's total pay fell by about 5%
Fierce Pharma
MARCH 12, 2024
Despite Moderna’s efforts to prove its mRNA thesis beyond COVID-19 in 2023, the post-pandemic hangover took a toll on the company. | Despite Moderna’s efforts to prove its mRNA thesis beyond COVID-19 in 2023, the post-pandemic hangover took a heavy toll on the company. In turn, much of the company’s top brass—including CEO Stéphane Bancel—saw their total compensation fall for the year.
Let's personalize your content